JOURNEY MEDICAL CORPORATION - COMMON STOCK

Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

10 Jan 2023 07:30:15 By Nasdaq GlobeNewswire

Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29

20 Dec 2022 07:30:55 By Nasdaq GlobeNewswire

Journey Medical Corporation to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference

05 Dec 2022 15:05:00 By Nasdaq GlobeNewswire

Journey Medical Corporation Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

10 Nov 2022 15:01:01 By Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Third Quarter 2022 Financial Results on November 10, 2022

03 Nov 2022 07:52:17 By Nasdaq GlobeNewswire

Journey Medical Corporation to Participate in Upcoming October 2022 Investor Conferences

04 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

30 Aug 2022 07:30:00 By Nasdaq GlobeNewswire

Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

09 Aug 2022 15:01:00 By Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Second Quarter 2022 Financial Results on August 9, 2022

03 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA®, AMZEEQ® and ZILXI® Patent Exclusivity

24 May 2022 07:30:00 By Nasdaq GlobeNewswire

Journey Medical Corporation to Present at the B. Riley Securities 22nd Annual Institutional Investor Conference

23 May 2022 07:30:00 By Nasdaq GlobeNewswire

Journey Medical Corporation Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

10 May 2022 15:01:00 By Nasdaq GlobeNewswire

Journey Medical Corporation to Announce First Quarter 2022 Financial Results on May 10, 2022

03 May 2022 15:15:00 By Nasdaq GlobeNewswire

Journey Medical Corporation to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities

04 Apr 2022 07:30:00 By Nasdaq GlobeNewswire

Journey Medical Corporation Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

23 Mar 2022 15:01:00 By Nasdaq GlobeNewswire

Journey Medical Corporation to Release Year End 2021 Financial Results and Provide Corporate Update on March 23, 2022

18 Mar 2022 12:15:00 By Nasdaq GlobeNewswire

Journey Medical Corporation Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Rosacea

17 Mar 2022 07:30:00 By Nasdaq GlobeNewswire

Journey Medical Corporation to Present at the 34th Annual ROTH Conference

09 Mar 2022 07:30:00 By Nasdaq GlobeNewswire

QBREXZA® (Rapifort® Wipes 2.5%) Receives Manufacturing and Marketing Approval in Japan Triggering $2.5 Million Milestone Payment to Journey Medical Corporation

11 Feb 2022 07:00:00 By Nasdaq GlobeNewswire

Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST)™ Franchise from VYNE Therapeutics, Inc.

13 Jan 2022 06:00:01 By Nasdaq GlobeNewswire